Literature DB >> 21383097

Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.

Guillermo Garcia-Effron1, Steven Park, David S Perlin.   

Abstract

Echinocandins are highly bound to serum proteins, altering their antifungal properties. The addition of 50% human serum to the MIC assay improves the identification of echinocandin-resistant Candida spp. harboring fks hot spot mutations. However, this modification cannot readily be applied to the method of the CLSI M27-A3 document due to safety and standardization difficulties. The aim of this study was to evaluate commercial bovine serum albumin (BSA) as a safe and standardized alternative to human serum. A collection of 28 echinocandin-susceptible strains, 10 Candida parapsilosis sensu lato strains (with naturally reduced echinocandin susceptibility), and 40 FKS hot spot mutants was used in this work. When RPMI 1640 was used for susceptibility testing, wild-type strains and fks mutants showed MIC range overlaps (-2, -1, and -3 2-fold-dilution steps separated these populations for anidulafungin, caspofungin, and micafungin, respectively). On the other hand, the addition of BSA to RPMI 1640 differentially increased echinocandin MIC values for these groups of strains, allowing better separation between populations, with no MIC range overlaps for any of the echinocandin drugs tested. Moreover, the use of RPMI-BSA reduced the number of fks hot spot mutant isolates for which MIC values were less than or equal to the upper limit for the wild type (very major errors) from 9, 2, and 7 with RPMI alone to 3, 0, and 3 for anidulafungin, caspofungin, and micafungin, respectively. When RPMI-BSA was used to study the susceptibility of C. parapsilosis sensu lato species to echinocandins, the strains behaved as anidulafungin- and micafungin-resistant isolates (MIC, ≥8 μg/ml). These data support the need for a revision of the CLSI protocol for in vitro testing of echinocandin susceptibility in order to identify all or most of the fks hot spot mutants. Also, caspofungin could be used as a surrogate marker of reduced susceptibility to echinocandins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21383097      PMCID: PMC3088269          DOI: 10.1128/AAC.01350-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

1.  Breakthrough invasive candidiasis in patients on micafungin.

Authors:  Christopher D Pfeiffer; Guillermo Garcia-Effron; Aimee K Zaas; John R Perfect; David S Perlin; Barbara D Alexander
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

2.  Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.

Authors:  Nathan P Wiederhold; Jodi L Grabinski; Guillermo Garcia-Effron; David S Perlin; Samuel A Lee
Journal:  Antimicrob Agents Chemother       Date:  2008-09-15       Impact factor: 5.191

3.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

4.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

5.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

6.  Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis.

Authors:  Peter G Pappas; Coleman M F Rotstein; Robert F Betts; Marcio Nucci; Deepak Talwar; Jan J De Waele; Jose A Vazquez; Bertrand F Dupont; David L Horn; Luis Ostrosky-Zeichner; Annette C Reboli; Byungse Suh; Raghunadharao Digumarti; Chunzhang Wu; Laura L Kovanda; Leah J Arnold; Donald N Buell
Journal:  Clin Infect Dis       Date:  2007-08-29       Impact factor: 9.079

7.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

8.  A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility.

Authors:  Guillermo Garcia-Effron; Santosh K Katiyar; Steven Park; Thomas D Edlind; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

9.  Role of plasma proteins in pharmacokinetics of micafungin, an antifungal antibiotic, in analbuminemic rats.

Authors:  Fumie Abe; Jun Ueyama; Noriyo Kawasumi; Masayuki Nadai; Tamon Hayashi; Miki Kato; Masafumi Ohnishi; Hiroko Saito; Naoshi Takeyama; Takaaki Hasegawa
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

10.  Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.

Authors:  Marie Desnos-Ollivier; Stéphane Bretagne; Dorothée Raoux; Damien Hoinard; Françoise Dromer; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

View more
  17 in total

1.  Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.

Authors:  Petros Ioannou; Aggeliki Andrianaki; Tonia Akoumianaki; Irene Kyrmizi; Nathaniel Albert; David Perlin; George Samonis; Dimitrios P Kontoyiannis; Georgios Chamilos
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

2.  Diverse nitrogen sources in seminal fluid act in synergy to induce filamentous growth of Candida albicans.

Authors:  Francisco J Alvarez; Kicki Ryman; Cornelis Hooijmaijers; Vincent Bulone; Per O Ljungdahl
Journal:  Appl Environ Microbiol       Date:  2015-02-06       Impact factor: 4.792

3.  Comparison of dimethyl sulfoxide and water as solvents for echinocandin susceptibility testing by the EUCAST methodology.

Authors:  Ana Alastruey-Izquierdo; Alicia Gómez-López; Maiken C Arendrup; Cornelia Lass-Florl; William W Hope; David S Perlin; Juan L Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2012-04-25       Impact factor: 5.948

4.  Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates.

Authors:  Cristina Jiménez-Ortigosa; Padmaja Paderu; Mary R Motyl; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

5.  Dose escalation studies with caspofungin against Candida glabrata.

Authors:  Marianna Domán; Renátó Kovács; David S Perlin; Gábor Kardos; Rudolf Gesztelyi; Béla Juhász; Aliz Bozó; László Majoros
Journal:  J Med Microbiol       Date:  2015-06-30       Impact factor: 2.472

6.  Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.

Authors:  Saad J Taj-Aldeen; Husam Salah; Winder B Perez; Muna Almaslamani; Mary Motyl; Atqah AbdulWahab; Kelley R Healey; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

Review 7.  Factors influencing susceptibility testing of antifungal drugs: a critical review of document M27-A4 from the Clinical and Laboratory Standards Institute (CLSI).

Authors:  Edinaira Sulany Oliveira de Sousa; Ana Claúdia Alves Cortez; Marcia de Souza Carvalho Melhem; Hagen Frickmann; João Vicente Braga de Souza
Journal:  Braz J Microbiol       Date:  2020-08-05       Impact factor: 2.476

8.  Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.

Authors:  Elisabetta Spreghini; Fiorenza Orlando; Maurizio Sanguinetti; Brunella Posteraro; Daniele Giannini; Esther Manso; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

9.  Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Authors:  Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros
Journal:  Mycopathologia       Date:  2017-07-11       Impact factor: 2.574

10.  Fluconazole assists berberine to kill fluconazole-resistant Candida albicans.

Authors:  De-Dong Li; Yi Xu; Da-Zhi Zhang; Hua Quan; Eleftherios Mylonakis; Dan-Dan Hu; Ming-Bang Li; Lan-Xue Zhao; Liang-Hua Zhu; Yan Wang; Yuan-Ying Jiang
Journal:  Antimicrob Agents Chemother       Date:  2013-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.